CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
Feasibility, Acceptability and Representativeness: Collecting Sociodemographic Data in CCTG Trials
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
CCTG is pleased to announce that the 2026 Annual Spring Meeting of Participants will be held April 24-26, 2026, at the Chelsea Hotel in Toronto.
The Canadian Cancer Trials Group (CCTG) has been awarded $742,052 for the PAC5 clinical trial in the CIHR Fall 2024 Project Grant competition. This phase III trial will test lanreotide for the prevention of one of the most severe complications of pancreatic surgery, postoperative pancreatic fistula (POPF).
“The PAC5 clinical trial has the potential to change the standard of care for postoperative pancreatic fistula prophylaxis, significantly benefiting patients and reducing healthcare system costs,” says CCTG Senior Investigator, Chris O’Callaghan.
Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2): study protocol for a phase 2, prospective, multicentre,open-label,multiarm, biomarker-directed,signal-seeking,umbrella,clinical trial for recurrent IDH mutant,grade 2/3 glioma
The 2024 - 2025 CCTG New Investigator Clinical Trial Practicum is now accepting applications!
The CCTG CO28 correlative study: Tumour-free ctDNA detection as a decision tool to support organ preservation in node-negative rectal cancer undergoing neoadjuvant chemotherapy, excision, and observation, was presented by Dr Jonathan Loree at GI ASCO 2025. This oral abstract assessed circulating tumor DNA (ctDNA) in patients with T1-T3, N0 rectal cancer and found that ctDNA effectively identifies cancers with inadequate response to chemotherapy for which a more radical surgery is recommended.
The recently opened ALC8 treatment trial will be testing the effects of novel therapeutics for newly diagnosed, untreated patients with acute myeloid leukemia (AML). Researchers want to compare the usual treatment for high-risk AML with four different combinations of treatment.
